Core Insights - Cytek Biosciences, Inc. announced preliminary, unaudited revenue results for Q4 and full year 2025, expecting total revenue of approximately $201 million for the year and about $62 million for Q4, reflecting growth of 8% year-over-year and 19% quarter-over-quarter [2][3] Financial Performance - The expected revenue for the full year 2025 is approximately $201 million [2] - Q4 2025 revenue of approximately $62 million shows an 8% increase compared to Q4 2024 and a 19% increase compared to Q3 2025 [2] Growth Drivers - The growth in Q4 2025 is attributed to strong performance in Services, Reagents, and instrument revenue in the Asia Pacific region, along with improved instrument sales in the US and EMEA [3] - The CEO highlighted a return to positive growth in instrument sales in EMEA during Q4 [3] Future Outlook - The company believes it is well-positioned for sustainable growth and profitability in the flow cytometry market [3] - Cytek plans to report comprehensive financial results for Q4 and full year 2025 and provide guidance for 2026 during an earnings call expected in late February 2026 [3] Company Overview - Cytek Biosciences specializes in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ technology to enhance cell analysis tools [5] - The company's product offerings include various flow cytometers, reagents, and software, aimed at providing integrated solutions for customers [5]

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences, Inc. is launching a two-part research support initiative to enhance accessibility to cell analysis amid reduced government funding and global economic challenges [1][2][3] Group 1: Initiative Details - The first phase involves awarding a three-laser Cytek Northern Lights™ flow cytometer, which utilizes Full Spectrum Profiling™ technology for versatile assays [2][3] - The second phase will introduce a grant program for funding eligible research projects, assessed through a merit-based process overseen by a scientific advisory board [3] Group 2: Collaboration and Impact - Cytek's initiatives are part of an ongoing collaboration with the International Society for Advancement of Cytometry (ISAC) to improve access to advanced cytometry tools globally [4] - A previous donation of a Cytek Northern Lights™ flow cytometer to a lab in Argentina exemplifies the impact of collaboration in empowering scientists in underserved communities [4] Group 3: Company Commitment - Cytek is dedicated to democratizing access to flow cytometry, ensuring that labs of all sizes and budgets can utilize advanced tools for cellular insights [5] - The company emphasizes the importance of community engagement alongside technological innovation to benefit the entire scientific community [5][7]